(Alliance News) - LungLife AI Inc on Tuesday said that it has completed enrolment for its prospective validation study of LungLB.

LungLife is a California-based developer of clinical diagnostic solutions designed to address the early detection of lung cancer.

LungLB is a test which uses a minimally invasive blood draw to deliver additional information to clinicians who are evaluating indeterminate lung nodules.

Since last February, 425 study participants have been enrolled from 17 sites across the US from academic medical centres and Veterans Affairs hospitals.

LungLife is now focused on preparing the data for detailed analysis, including working with each clinical site to finalise monitoring of study data before it is unblinded. In line with expectations, it estimates this process will take between three and four months.

Following this, the company will seek to publish the study findings in a peer-reviewed medical journal.

"Completing enrolment is a considerable milestone along the path to commercialisation, and we are pleased that we continue to remain on-track with the timeline set out at IPO," said Chief Executive Officer Paul Pagano.

"We would like to thank our clinical investigators and their teams, and importantly the study participants, for taking part in our trial and for their continued support with study close-out."

LungLife AI shares were flat at 45.00 pence each in London on Tuesday morning.

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.